Goldman Sachs Added Eli Lilly (LLY) to their Conviction Buy List
More News related to LLY
- Top 10 News Items 10/6-10/10: Dow Plunges 18% This Week; UK to Inject Capital Into Banking System; Iceland Melts-down, Seizes Largest Bank
- Healthcare Resources Available in Difficult Times
- Lilly Recognized as One of the World's Top Biopharmaceutical Employers
- Credit Suisse Downgrades Eli Lilly (LLY) to Neutral
- David Moenning's Daily State of the Markets: 10/10
More News related to Analyst Comments
- AmTech's Top 12 Fundamental Picks (RIMM, FSLR, MELI, QCOM, more..)
- Pali Research Maintains 'Buy' Rating on Sohu.com (SOHU), Lowers Price Target and 2009 Estimates
- Pali Research Maintains 'Buy' Rating on Sina Corp (SINA), but Slashes Earnings Estimates and Price Target
- Davenport Maintains 'Strong Buy' Rating on Kaiser Aluminum (KALU), But Cut Earnings Estimates and Price Target
- Davenport Maintains 'Strong Buy' Rating on Harsco (HSC), Lowers Price Target and Earnings Estimates
Goldman Sachs added Eli Lilly (NYSE: LLY) to their Conviction Buy List.
Eli Lilly and Company engages in the discovery, development, manufacture, and sale of pharmaceutical products worldwide.
Related Categories
Analyst CommentsStocks Mentioned
+4.50Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
